Werewolf Therapeutics
HOWL
51 hedge funds and large institutions have $228M invested in Werewolf Therapeutics in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 21 increasing their positions, 7 reducing their positions, and 3 closing their positions.
300% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 3
200% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 7
21% more funds holding
Funds holding: 42 → 51 (+9)
0.46% more ownership
Funds ownership: 68.94% → 69.4% (+0.46%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
30% less capital invested
Capital invested by funds: $326M → $228M (-$98.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$13.7M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.39M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.17M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$2M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$12M |
| 2 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$7.53M |
| 3 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$5.08M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$2.16M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$2.11M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $153 | +$194K | +12,831 | New |
|
|
NIP
52
Nicholas Investment Partners
Rancho Santa Fe,
California
| – | -$5.08M | -296,283 | Closed |
|
|
53
Russell Investments Group
London,
United Kingdom
| – | -$2.16M | -125,873 | Closed |
|
|
LCS
54
Levin Capital Strategies
New York
| – | -$257K | -15,000 | Closed |
|
HOWL Hedge Fund Activity: Q4 2021 in Review
51 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q4 2021, worth a combined $228M — down 30% from $326M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new HOWL positions and 3 closed out — a net gain of 9 holders — while 21 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock, adding an estimated $13.7M. The largest seller was Deerfield Management, cutting an estimated $12M.
- 51 institutional investors held Werewolf Therapeutics (HOWL) as of Q4 2021, up from 42 in Q3 2021.
- Funds reported $228M of Werewolf Therapeutics stock for Q4 2021, down 30% quarter-over-quarter.
- 12 funds opened new Werewolf Therapeutics positions in Q4 2021 and 3 closed out, a net change of +9 holders.
- The largest Werewolf Therapeutics buyer in Q4 2021 was BlackRock, an estimated $13.7M added.
- The largest Werewolf Therapeutics seller in Q4 2021 was Deerfield Management, an estimated $12M sold.
Based on aggregated 13F filings for Q4 2021.